Hospitals using the BD MaxPlus™ needle-free connector had lower unadjusted central line-associated bloodstream infection (CLABSI) rates, as well as lower standardised infection ratios, compared to hospitals not using the MaxPlus technology.*1
true
Support
West Africa
+233 302 769 692
West Africa Secant Tower West Wings, 4th Floor, Secant Tower, Plot #398, Papa Monrovia Street, 7th Lane Osu Kuku Hills, Accra Ghana
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
East Africa
+254 20 2738339/40
Africa Re Center, 2nd FL, Hospital Rd, Upper Hill, P.O. Box 76613 – 00508, Nairobi, Kenya
+254 758 726613
East & West Africa
ODE.africa@bd.com
serviceclaims.africa@bd.com
South Africa
+27 10 201 7400
20 Woodlands Drive, The Woodllands Office Park Build 6 (G), Woodmead, Johannesburg, Gauteng, 2191
orderssa@bd.com
BD MaxPlus™ needle-free connector
Choose the only needle-free connector with an FDA-cleared label statement demonstrating a reduction in CLABSI
- Overview
- EIFU & Resources
true
Solid sealed surface
The solid sealed surface withstands 7 days/200 activations.
Clear housing
The clear design shows the complete fluid pathway, enabling optimal visibility when flushing.
No interstitial space
Zero interstitial space between the components limits opportunities for microbial ingress.
Zero-reflux action
Zero-reflux feature upon disconnection can help reduce catheter occlusions and catheter occlusions
.png)
true
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
Case Studies
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Learn more
true
Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.
* 2013 CMS hospital compare data from 3,074 hospitals, accounting for nearly 11,000 CLABSIs associated with nearly 10 million catheter days.
- Tabak YP, Johannes RS, Sun X, Crosby CT, Jarvis WR. Innovative use of existing public and private data sources for postmarket surveillance of central line-associated bloodstream infections associated with intravenous needleless connectors. J Infus Nurs. 2016;39(5):328-335.
BD-35577 (08/2021)
true